Loading patent…
AssigneeThe Regents of the University of California
InventorsYvonne Yu-Hsuan Chen, Ximin Chen, Laurence Chen
Estimating the term…
Aspects of the disclosure relate to novel scFv molecules that are useful for incorporation into novel chimeric antigen receptors with enhance anti-tumor activity. Further aspects relate to a polypeptide comprising a CAR comprising, in order from amino proximal to carboxy proximal end, a scFv, a transmembrane domain, a torsional linker, and a cytoplasmic region comprising a primary intracellular signaling domain, wherein the torsional linker comprises 1-12 alanine residues. Also described are nucleic acids comprising a sequence encoding a polypeptide of the disclosure, vectors, such as lentiviral vectors comprising the nucleic acids of the disclosure, cells comprising and/or expressing nucleic acids and/or polypeptides of the disclosure, and populations of cells comprising the cell embodiments of the disclosure. Also provided are methods of making cells that express a polypeptide and methods of treating patients with the polypeptides and cell compositions of the disclosure.
A method of treating a patient with brain cancer, comprising administering to the patient a population of cells that express a polypeptide comprising an anti-CD20 single chain variable fragment (scFv) comprising:
A method of treating a patient with brain cancer, comprising administering to the patient a population of cells that express a polypeptide comprising a CAR comprising, in order from amino proximal to carboxy proximal end, an anti-CD20 scFv, a CD28 transmembrane domain, a torsional linker, and a cytoplasmic region comprising a CD28 costimulatory domain and a CD3-zeta intracellular signaling domain, wherein the torsional linker comprises 1-12 alanine residues, wherein the anti-CD20 scFv comprises
Dependencies are inferred from the claim text.